Introduction C ardiovascular disease (CVD) is a major contributor to death worldwide, 1 affected by the atherosclerotic process that has already started in childhood. 2 Thus, for risk factors such as high blood total cholesterol (TC), blood glucose (BG) and blood pressure (BP), it is important both to reduce high levels and to maintain low values. 2 However, moderately elevated levels of these risk factors are rarely symptomatic or give symptoms that tend to be easily ignored. Although early diagnosis of elevated levels can be accomplished through relatively inexpensive measurements of TC, BG and BP, many people remain untreated. The majority of individuals with familial hypercholesterolemia and over 50% of individuals with type 2 diabetes mellitus are undiagnosed. 3, 4 Most premature CVDs are preventable by a healthy diet, and avoiding tobacco, alcohol abuse and insufficient physical activity in addition to adequate drug treatment. 5 However, without knowing one's risk factor levels, targeted decisions to lower risk are not possible. 6 The lower thresholds being recommended in current guidelines for medical treatment of elevated risk factors in an aging world population, imply that even more people will need treatment in the years to come. 7, 8 Existing health care services may not easily have the capacity to deal with the increasing number of medical visits. 9 Thus, the World Health Organization (WHO) calls for local, novel approaches to deliver health care services. 10 Community pharmacies (pharmacies) have been suggested to play a role in CVD prevention, as they now perform some services which had earlier been reserved for physicians. 11 This includes, among many others, measurements of TC and other lipids, BG and BP, in addition to providing lifestyle advice and counseling on smoking cessation. 12 Using TC concentrations and questionnaire information obtained in a TC screening study in pharmacies, our aim was to investigate yield in terms of detecting unknown high TC and characteristics and prevalence of those whose TC, BG and BP had not previously been measured. We hypothesized that a pharmacy-based TC screening study would:
(1) Attract individuals with characteristics similar to the general population. (2) Identify people whose TC, BG and BP have not been measured before and where a substantial number would get new and useful information on their TC level.
Methods
This cross-sectional TC screening study is part of the 'Vascular lifestyle-Intervention and Screening in pharmacies' (VISA) study. A complete and detailed description of the VISA study design is appended (Supplementary appendix S1). Briefly, the data analyzed in this paper arose from complimentary TC measurements and questionnaires offered 6 days in both 2012 and 2014 in Boots TM Norge AS community pharmacies. All pharmacies belonging to the Boots pharmacy chain (148 in 2012 and 149 in 2014) distributed across Norway, participated. The study was planned and conducted by the University of Oslo in collaboration with the for-profit organizations Boots, Mills AS, Grete Roede TM , and a non-profit organization, the Norwegian Health Association. Participants became aware of the screening through national or locally means of advertisements. Health care providers in pharmacies (pharmacist, technicians or nurses) who had completed a training program consisting of a web-based educational module and practical training, executed the study.
The initial step in the TC screening study was to undergo pointof-care finger-prick TC measurements in a consultation room within each pharmacy. TC was measured using the Roche Diagnostics AS Accutrend Plus TM (available in all pharmacies) or the Alere AS Afinion TM AS100 (available in 50 pharmacies in 2014). Accutrend Plus captured TC concentrations of 3.88-7.76 mmol/L, and Afinion AS100 in the interval 2.59-12.95 mmol/L. All screenees were immediately provided with their TC value on completion of the assay along with an interpretive brochure with diet and lifestyle advice for CVD prevention developed by the VISA-study investigators. 13 For those with TC !7.76 mmol/L, a follow-up visit with a general practitioner (GP) was recommended.
Research study participation also depended on filling out an anonymous optically readable pre-coded questionnaire that was solicited when convenient during screening (translated versions of the questionnaire are appended). This screening questionnaire was developed by the VISA-study investigators, however, wording of the questions were borrowed from several validated questionnaires and from Statistics Norway (www.ssb.no). As approved by the Norwegian Regional Ethical Committee, consent for research participation was assumed by filling out the questionnaire. For statistical analyses, we used the following items: Reporting of this paper follows the STROBE checklist for observational studies.
Study sample
Inclusion criteria were age !18 years, not being pregnant or lactating. In total 28 263 of screenees completed the questionnaire (18 624 in 2012 and 9639 in 2014). Only people who were not taking lipidlowering medication were screened in 2014; consequently all those reported using lipid-lowering medication in 2012 were excluded from these analyses. Those with multiple unrealistically high/low/ missing values or who had an unreadable questionnaire were also omitted, leading to a final inclusion of 21 090 participants (figure 1).
Data analysis
Descriptive statistics for the continuous variables were given as mean and standard deviation (SD), whereas categorical variables were expressed as frequencies and percentages. For comparison with the Norwegian population, the majority of data were obtained from Statistics Norway (the agency which has responsibility for official statistics in Norway). Due to lack of recent national data, TC concentration obtained from the most recent Tromsø-study (2015-2016) was used as reference for the Norwegian population. The Tromsø study is a longitudinal population study performed in the urban, northern part of Norway.
14 We utilized two cut offs for high TC: TC concentrations of !7.0 mmol/L indicated a probable need for treatment, 15 whereas TC !6.2 mmol/L indicated that TC should be monitored because of the risk of developing higher TC. 16 Missing values for smoking were assumed to indicate non-smoking, because the smoking question in the 2012 edition was constructed as if it should only be checked if smokers: 'Do you smoke? About how many per day:' Similarly, missing values were taken to indicate 'not measured' for previously measured TC, BG and BP.
Statistical analysis included Chi-square test, independent sample t-test and logistic regression. For logistic regression, estimated probabilities (back transformed from their estimated logit) and odds ratios (OR) with corresponding 95% confidence intervals (95% CI) were presented. The difference between age-and sexadjusted models and more fully adjusted models was minor, and the fully adjusted models (age, gender, BMI and education, smoking, physical inactivity and previous measures of the other two risk factors and TC categories for TC) were presented. All analyses were conducted using SAS version 9.4 for Windows. The significance level was set at 0.05. Table 1 shows background characteristics. The majority (68.9%) was women, and mean age was 54.5 years (AE16.0). Overweight/obesity defined as BMI !27 kg/m 2 (following the convention of Statistics Norway), was more prevalent in men (37.4%, n = 2356) than in women (26.0%, n = 3529). The VISA study attracted older women but educational level (in particular percentage with high school as highest attained educational level), smoking, BMI !27 kg/m 2 and inactivity were similar to Statistics Norway's national data (table 1) .
Results

Population characteristics
Yield of screening
Total cholesterol
Prevalence of high TC defined as !7.0 mmol/L was observed in 0.9%, (n = 18) of women and 1.4% (n = 8) of men aged 18-29, as well as in 38.2% (n = 779) and 30.1% (n = 167) of women and men respectively, aged 60-69 years (figure 2). Table 2 presents the yield of the screening for unknown high TC. In total, 11.4% (n = 2337) learned that their TC level was high (!7.0 mmol/L), whereas an additional 1.6% (n = 335) had a reinforced message, given that they already knew their TC was high. Characteristics of this group was similar to the total study sample, except for slightly older age (57-63 years) and a higher percentage of low-educated (16-22% with primary school).
With high TC defined as !6.2 mmol/L, 19.4% (N = 3975) of the total sample were alerted of their high TC, whereas 7.3% (n = 1501) already knew that their TC was !6 mmol/L.
Witihin age groups, 0.24% (n = 50) aged 18-29 years were made aware of an unknown elevated TC (!6.2 mmol/L). The yield of detecting unknown high TC was however largest with 5.7% (n = 1174) for 60-69 years old.
Likelihood of previous measurement
In total, 36.2% (n = 7638) had measured TC, BG and BP previously, whereas 6.6% (n = 1401) had not measured any of these before. Measuring one risk factor before was the strongest predictor of whether or not either of the others also had been measured. If TC Figure 1 Simplified flowchart of the study design and inclusion of participants in an in-pharmacy screening for total cholesterol had not been measured before, there was an observed 53% probability [OR 2.61 (95% CI: 2.43-2.80)] that BG had not been measured, and a 64% probability [OR 3.00 (95% CI: 2.65-3.39)] that BP had not been measured before. Being young, inactive, having low educational level, and being overweight/obese were all characteristics that were significantly associated with the odds of not having had TC measured before. Those whose measured TC 5.0 mmol/L (which was only known after the screening in this study) had a 2-fold increased odds of not having had TC measured before [OR 2.01 (95% CI: 1.80-2.32)] compared with those who had measured TC !7.0 mmol/L. In contrast to TC and BP, age was not a strong predictor for the probability of previous BG measurement, but being male and normal weight were, as these characteristics were significantly associated with increased probability that BG had not previously been measured. The probability that BP had not previously been measured was overall low (8% for men and 6% for women) (Supplementary tables S3-S5).
Discussion
We replicated what is well established, 17 and recently confirmed in the latest Tromsø Study, 14 that women's TC level peaks later than for men.
In Norway, the latest information on measured TC in multiple counties were reported more than 10 years ago (5.6 mmol/L), and this study reported that TC remained about same (5.5 mmol/L). 18 Compared with other longitudinal population health studies in Norway with similar age (but more equal gender) distribution, TC in the nationwide VISA study was also similar to the latest (2006-08) NordTrøndelag Health Study (rural county in Norway) with mean TC 5.4 mmol/L 19, 20 and the Tromsø Study (5.5 mmol/L). 14 Furthermore, prevalence of high TC was highest in women and higher than other pharmacy screenings. 21 Compared with health surveys in Sweden (1986-2009), we observed similar prevalence of TC !7.0 mmol/L for women over a similar age range and slightly lower prevalence for men. 22 However, in contrast to the mentioned population health studies, the VISA-study population was non-medicated.
Results from the yield of screening (to whom useful and new knowledge of high TC was given) can be used to develop strategies to target those who would benefit the most from the screening. We found that 11% received new information, and an additional 2% got repeated information about a TC level !7.0 mmol/L that should be treated. 15 Their characteristics were similar to the general study population although slightly older and with a higher percentage of low educated. An additional 8% were informed about a previously unknown TC !6.2 mmol/L that should be monitored given the tendency for TC to increase with age, and the risks associated with long-term exposure of high TC. 2 Thus, the 0.3% young who were identified with a previously unknown TC of !6.2 mmol/L may be of special importance despite that the yield is low in absolute numbers. Attention to high risk in the young may also be of special importance in Norway given a reported recent increase in first myocardial infarction among people aged 45 years. 23 Since only physicians can diagnose and prescribe medication, yields of a pharmacy-based screening in a public health perspective also depend on ability to collaborate with physicians and other appropriate professionals.
We found that the likelihood that TC and BG were not previously measured were about twice as high as for BP. These findings are supported by a similar study in pharmacies in Austria. 12 Future studies should explore possible barriers for why finger-prick measurements of TC and BG seems to be less frequent measures than BP. For TC, our results indicate that future screenings should target young men and women with low education and overweight, to reach those who are less likely to have measured TC previously and most importantly, those with unknown high TC. Whereas for BG, males in all ages that are normal weight should be targeted. Young males and immigrants are also less likely to visit their GP than their counterparts. 24 At the same time, pharmacies and other retail-based clinics have longer opening hours and offer affordable drop-in appointments for health services, 25 which are features that are seen to attract young and those with low education. 26 According to our data, measurement of one risk factor was associated with measuring other risk factors. These findings call for attention to the importance of initial screening for CVD risk factors. This should be highlighted in countries without governmental-initiated health surveys, in light of the recent observed unfavorable increase in TC levels in Finland 27 and in Sweden. 28 
Strengths and limitations
First, we acknowledge that pharmacies are not research institutions. However, pharmacies seem highly accessible and successful in recruiting participants across geographical regions, age, sex and educational status. Like any other study based on voluntary enrollment of participants, screening in pharmacies may be subject to selection bias. However, although there was an overrepresentation of middleage women, we showed that age, gender and education biases may be similar to other conventional health studies, 29, 30 and highly comparable with another pharmacy-based screening program in Austria. 12 We also note that pharmacies have a broad product assortment in addition to prescription medicines, and that the customers are accordingly not limited to medicated patients with a diagnosis. 25 The use of chain pharmacies 31 might be a strength of the study as it ensures consistency in training and monitoring of compliance to the protocol. Questionnaire limitations include that it was not validated and it was self-administered and only TC was objectively measured. There are several errors associated with self-reporting. However, self-report is quick and inexpensive and with few questions considered to be sensitive, this limitation may not be of great impact. 32 We did find some peculiar findings that might indicate that the participants interpreted the question of previously measured TC incorrectly (e.g. that subsequently measured low TC was associated with being less likely to have measured TC before). Another limitation was that we omitted all participants with an unreadable questionnaire and with unrealistic values of key variables. Also, different exclusion criteria in the two screening periods lead to later exclusion of potential participants. Exclusions were however performed to improve data quality and for comparison basis. Inconsistency in which time of the day and time of the year TC was measured, and the use of two different measurement devices with different precision levels may have affected the mean TC concentration. In total 7.9% (n = 1660) reported in 2014 that they had previously measured their TC in pharmacies. Hence it is likely that these 1660 people are represented twice in the material, which could influence the analyses and interpretations of results.
Potential role of pharmacies
This study demonstrates potential for pharmacies to complement the health care system by providing the important initial screening and advice for CVD risk factors. 11 Although, the TC screening in this study was complementary, and results might therefore not be representative for the usual pay-service of TC measurement in pharmacies. Similar pharmacist-provided interventions are demonstrated to be successful in reducing risk of CVDs. 33 This potential role of pharmacies should be recognized in countries were the health care system is already stressed with long waiting times, and where an aging population will further stress the expansion of current health care systems. 8 Results from a study in Canada, with similar universal health care system as Norway, found that adding pharmacists to primary care was also a cost effective strategy for reducing CVD risk. 34 Hence, expenses for marketing, staff and blood tests and the pharmacies' willingness to assess CVD risk factors must be considered and compared with potential yields of this and future in-pharmacy screenings. Future screenings in pharmacies should consider using the current results in developing strategies to reach those that could be expected to benefit the most from screening. In this regard, the screening questionnaire could be used to consider whether those who have already measured their CVD risk factors are reasonable to measure again.
Conclusion
We present a pharmacy-based screening for TC and previous assessment of CVD risk factors. The screening seems to be convenient in terms of attracting a large number of people across educational levels but with an overrepresentation of middle-aged women. The yield of identifying high TC that may need treatment in a non-medicated sample was substantial in absolute numbers, whereas 11-19% were unaware of their high TC levels of !7.0 and 6.2 mmol/L, respectively. We found that prior measurement of TC and BG was less common than for BP. To increase the yield in terms of attracting those whose TC and BG are more likely not to have been measured before, our results suggest that young, overweight/obese males and females should be targeted for TC screening, and normal weight males in all ages for BG screening. It seems that point-of-care testing in pharmacies is convenient. Further studies are warranted to evaluate whether pharmacy-screening could be an asset to the health care system.
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Key points
Screening for CVD risk factors in Norwegian community pharmacies resulted in alerting 11-19% of total cholesterol concentrations that need attention. A community pharmacy-based screening study was efficient and successful in recruiting >20 000 that seemed representative for at least, but not limited to the middle-aged female Norwegian population.
Results from an in-pharmacy screening emphasize the importance of initial screening for CVD risk factors and to tailor future screening to target groups to reach those that would be most useful to screen. Screening and identification of high risk of CVD in community pharmacies hold considerable promise for contributing to improve public health.
